메뉴 건너뛰기




Volumn 4, Issue 4, 2010, Pages 435-444

Aztreonam lysine: A novel inhalational antibiotic for cystic fibrosis

Author keywords

aerosolized antibiotics; aztreonam; cystic fibrosis; delivery system; nebulized antibiotics; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ARD 3100; ARIKACE; AZITHROMYCIN; AZTREONAM; BRAMITOB; CARBAPENEM; CAYSTON; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; DEOXYRIBONUCLEASE; FOSFOMYCIN; GLYCOPEPTIDE; GS 9310; IBUPROFEN; LEVOFLOXACIN; MACROLIDE; MP 376; PENICILLIN G; POLYMYXIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

EID: 77955047596     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.10.48     Document Type: Review
Times cited : (20)

References (66)
  • 1
    • 63249110872 scopus 로고    scopus 로고
    • Update in cystic fibrosis 2008
    • Ratjen F. Update in cystic fibrosis 2008. Am. J. Respir. Crit. Care Med. 179(6), 445-448 (2009).
    • (2009) Am. J. Respir. Crit. Care Med. , vol.179 , Issue.6 , pp. 445-448
    • Ratjen, F.1
  • 2
    • 70349815600 scopus 로고    scopus 로고
    • Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005
    • Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005. Chest 136(6), 1554-1560 (2009).
    • (2009) Chest , vol.136 , Issue.6 , pp. 1554-1560
    • Razvi, S.1    Quittell, L.2    Sewall, A.3    Quinton, H.4    Marshall, B.5    Saiman, L.6
  • 4
    • 12844270608 scopus 로고    scopus 로고
    • Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis
    • Li Z, Kosorok MR, Farrell PM et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293(5), 581-588 (2005).
    • (2005) JAMA , vol.293 , Issue.5 , pp. 581-588
    • Li, Z.1    Kosorok, M.R.2    Farrell, P.M.3
  • 5
    • 0025355607 scopus 로고
    • Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa
    • Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 116(5), 714-719 (1990).
    • (1990) J. Pediatr. , vol.116 , Issue.5 , pp. 714-719
    • Kerem, E.1    Corey, M.2    Gold, R.3    Levison, H.4
  • 6
    • 70350446684 scopus 로고    scopus 로고
    • Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations
    • Flume PA, Mogayzel PJ, Robinson KA et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 180(9), 802-808 (2009).
    • (2009) Am. J. Respir. Crit. Care Med. , vol.180 , Issue.9 , pp. 802-808
    • Flume, P.A.1    Mogayzel, P.J.2    Robinson, K.A.3
  • 7
    • 39049142717 scopus 로고    scopus 로고
    • Exacerbations in cystic fibrosis: 3 - Management
    • Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3 - management. Thorax 63(2), 180-184 (2008).
    • (2008) Thorax , vol.63 , Issue.2 , pp. 180-184
    • Smyth, A.1    Elborn, J.S.2
  • 8
    • 0020573198 scopus 로고
    • Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
    • Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr. Scand. 72(5), 651-657 (1983). (Pubitemid 13048784)
    • (1983) Acta Paediatrica Scandinavica , vol.72 , Issue.5 , pp. 651-657
    • Szaff, M.1    Hoiby, N.2    Flensborg, E.W.3
  • 9
    • 0034107646 scopus 로고    scopus 로고
    • Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs
    • Elborn JS, Prescott RJ, Stack BH et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 55(5), 355-358 (2000).
    • (2000) Thorax , vol.55 , Issue.5 , pp. 355-358
    • Elborn, J.S.1    Prescott, R.J.2    Stack, B.H.3
  • 10
    • 0002101312 scopus 로고
    • Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; Observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol
    • di Sant Agnese PA, Anderson D. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am. J. Dis. Child. 72, 17-61 (1946).
    • (1946) Am. J. Dis. Child. , vol.72 , pp. 17-61
    • Di Sant Agnese, P.A.1    Anderson, D.2
  • 11
    • 0034828531 scopus 로고    scopus 로고
    • Formulation of aerosolized therapeutics
    • Kuhn RJ. Formulation of aerosolized therapeutics. Chest 120(3 SUPPL.), 94S-98S (2001).
    • (2001) Chest , vol.120 , Issue.3 SUPPL.
    • Kuhn, R.J.1
  • 12
    • 0033531143 scopus 로고    scopus 로고
    • Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group
    • Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1), 23-30 (1999).
    • (1999) N. Engl. J. Med. , vol.340 , Issue.1 , pp. 23-30
    • Ramsey, B.W.1    Pepe, M.S.2    Quan, J.M.3
  • 13
    • 50849131275 scopus 로고    scopus 로고
    • Shifting patterns of inhaled antibiotic use in cystic fibrosis
    • Moskowitz SM, Silva SJ, Mayer-Hamblett N et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr. Pulmonol. 43(9), 874-881 (2008).
    • (2008) Pediatr. Pulmonol. , vol.43 , Issue.9 , pp. 874-881
    • Moskowitz, S.M.1    Silva, S.J.2    Mayer-Hamblett, N.3
  • 14
    • 0034835277 scopus 로고    scopus 로고
    • Microbiological and immunologic considerations with aerosolized drug delivery
    • LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest 120(3 SUPPL.), 118S-123S (2001).
    • (2001) Chest , vol.120 , Issue.3 SUPPL.
    • Lipuma, J.J.1
  • 16
    • 65949124667 scopus 로고    scopus 로고
    • Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis
    • Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest 135(5), 1223-1232 (2009).
    • (2009) Chest , vol.135 , Issue.5 , pp. 1223-1232
    • Retsch-Bogart, G.Z.1    Quittner, A.L.2    Gibson, R.L.3
  • 17
    • 77950881382 scopus 로고    scopus 로고
    • Cystic Fibrosis Trust Cystic Fibrosis Trust, Kent, UK
    • Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2008. Cystic Fibrosis Trust, Kent, UK (2009).
    • (2009) UK CF Registry Annual Data Report 2008
  • 18
    • 60449117029 scopus 로고    scopus 로고
    • High treatment burden in adults with cystic fibrosis: Challenges to disease self- management
    • Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self- management. J. Cyst. Fibrosis 8(2), 91-96 (2009).
    • (2009) J. Cyst. Fibrosis , vol.8 , Issue.2 , pp. 91-96
    • Sawicki, G.S.1    Sellers, D.E.2    Robinson, W.M.3
  • 20
    • 0023607439 scopus 로고
    • Selection and properties of Pseudomonas aeruginosa variants resistant to p-lactam antibiotics
    • Cullman W, Buscher KH, Dick W. Selection and properties of Pseudomonas aeruginosa variants resistant to p-lactam antibiotics. Eur. J. Clin. Microbiol. 6(4), 467-473 (1987).
    • (1987) Eur. J. Clin. Microbiol. , vol.6 , Issue.4 , pp. 467-473
    • Cullman, W.1    Buscher, K.H.2    Dick, W.3
  • 21
    • 27144521603 scopus 로고    scopus 로고
    • Simple method to determine p-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test
    • Vedel G. Simple method to determine p-lactam resistance phenotypes in Pseudomonas aeruginosa using the disc agar diffusion test. J. Antimicrob. Chemother. 56(4), 657-664 (2005).
    • (2005) J. Antimicrob. Chemother. , vol.56 , Issue.4 , pp. 657-664
    • Vedel, G.1
  • 22
    • 34948828022 scopus 로고    scopus 로고
    • Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections
    • Hocquet D, Berthelot P, Roussel- Delvallez M et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother. 51(10), 3531-3536 (2007).
    • (2007) Antimicrob. Agents Chemother. , vol.51 , Issue.10 , pp. 3531-3536
    • Hocquet, D.1    Berthelot, P.2    Roussel-Delvallez, M.3
  • 23
    • 33646453620 scopus 로고    scopus 로고
    • Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates
    • Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50(5), 1633-1641 (2006).
    • (2006) Antimicrob. Agents Chemother. , vol.50 , Issue.5 , pp. 1633-1641
    • Quale, J.1    Bratu, S.2    Gupta, J.3    Landman, D.4
  • 24
    • 0032804038 scopus 로고    scopus 로고
    • Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis
    • Shawar RM, MacLeod DL, Garber RL et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43(12), 2877-2880 (1999).
    • (1999) Antimicrob. Agents Chemother. , vol.43 , Issue.12 , pp. 2877-2880
    • Shawar, R.M.1    MacLeod, D.L.2    Garber, R.L.3
  • 25
    • 0016611606 scopus 로고
    • Cystic fibrosis: Comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride)
    • Dietzsch HJ, Gottschalk B, Heyne K, Leupoid W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 55(1), 96-100 (1975).
    • (1975) Pediatrics , vol.55 , Issue.1 , pp. 96-100
    • Dietzsch, H.J.1    Gottschalk, B.2    Heyne, K.3    Leupoid, W.4    Wunderlich, P.5
  • 26
    • 77955040567 scopus 로고    scopus 로고
    • Reduced treatment time for colistinmethate sodium solutions (colistin CF) aerosolized by eFlow rapid, a novel electronic nebulizer
    • Presented at: Copenhagen, Denmark 15-18 June
    • Keller M, Hug M, Bietterle E, Bucholski A. Reduced treatment time for colistinmethate sodium solutions (colistin CF) aerosolized by eFlow rapid, a novel electronic nebulizer. Presented at: 29th European Cystic Fibrosis Conference. Copenhagen, Denmark, 15-18 June 2006.
    • (2006) 29th European Cystic Fibrosis Conference
    • Keller, M.1    Hug, M.2    Bietterle, E.3    Bucholski, A.4
  • 28
    • 33745686502 scopus 로고    scopus 로고
    • Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
    • Gibson RL, Retsch-Bogart GZ, Oermann C et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. 41(7), 656-665 (2006).
    • (2006) Pediatr. Pulmonol. , vol.41 , Issue.7 , pp. 656-665
    • Gibson, R.L.1    Retsch-Bogart, G.Z.2    Oermann, C.3
  • 30
    • 0034771411 scopus 로고    scopus 로고
    • Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis
    • Rosenfeld M, Gibson R, McNamara S et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J. Pediatr. 139(4), 572-577 (2001).
    • (2001) J. Pediatr. , vol.139 , Issue.4 , pp. 572-577
    • Rosenfeld, M.1    Gibson, R.2    McNamara, S.3
  • 31
    • 55549131738 scopus 로고    scopus 로고
    • In vitro performance of eFlow, an electronic inhaler for administration of a novel aztreonam formulation to CF patients
    • Bucholski A, Keller M, Balcke A et al. In vitro performance of eFlow, an electronic inhaler for administration of a novel aztreonam formulation to CF patients. Pediatr. Pulmonology S25(37), 321 (2003).
    • (2003) Pediatr. Pulmonology , vol.S25 , Issue.37 , pp. 321
    • Bucholski, A.1    Keller, M.2    Balcke, A.3
  • 33
    • 0021368586 scopus 로고
    • Lack of cross-reactivity between aztreonam , a monobactam antibiotic, and penicillin in penicillin-allergic subjects
    • Saxon A, Hassner A, Swabb EA, Wheeler B, Adkinson NF Jr. Lack of cross-reactivity between aztreonam , a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J. Infect. Dis. 149(1), 16-22 (1984).
    • (1984) J. Infect. Dis. , vol.149 , Issue.1 , pp. 16-22
    • Saxon, A.1    Hassner, A.2    Swabb, E.A.3    Wheeler, B.4    Adkinson Jr., N.F.5
  • 34
    • 0021910322 scopus 로고
    • Investigation into the immunologic cross-reactivity of aztreonam with other p-lactam antibiotics
    • Saxon A, Swabb EA, Adkinson NF Jr. Investigation into the immunologic cross-reactivity of aztreonam with other p-lactam antibiotics. Am. J. Med. 78(2A), 19-26 (1985).
    • (1985) Am. J. Med. , vol.78 , Issue.2 A , pp. 19-26
    • Saxon, A.1    Swabb, E.A.2    Adkinson Jr., N.F.3
  • 35
    • 0025861107 scopus 로고
    • Safety of aztreonam in patients with cystic fibrosis and allergy to p-lactam antibiotics
    • Jensen T, Pedersen SS, Hoiby N, Koch C. Safety of aztreonam in patients with cystic fibrosis and allergy to p-lactam antibiotics. Rev. Infect. Dis. 13(SUPPL. 7), S594-S597 (1991).
    • (1991) Rev. Infect. Dis. , vol.13 , Issue.SUPPL. 7
    • Jensen, T.1    Pedersen, S.S.2    Hoiby, N.3    Koch, C.4
  • 36
    • 38349058630 scopus 로고    scopus 로고
    • A Phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
    • Retsch-Bogart GZ, Burns JL, Otto KL et al. A Phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol. 43(1), 47-58 (2008).
    • (2008) Pediatr. Pulmonol. , vol.43 , Issue.1 , pp. 47-58
    • Retsch-Bogart, G.Z.1    Burns, J.L.2    Otto, K.L.3
  • 37
    • 73449119635 scopus 로고    scopus 로고
    • Effect of multiple courses of aztreonam lysine for inhalation (AZLI) on FEVt and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006
    • Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, Montgomery AB. Effect of multiple courses of aztreonam lysine for inhalation (AZLI) on FEVt and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006. J. Cyst. Fibrosis 8 (SUPPL. 2), S28 (2009).
    • (2009) J. Cyst. Fibrosis , vol.8 , Issue.SUPPL. 2
    • Oermann, C.M.1    McCoy, K.S.2    Retsch- Bogart, G.Z.3    Gibson, R.L.4    Montgomery, A.B.5
  • 38
    • 77955034678 scopus 로고    scopus 로고
    • Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): Effect on disease related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)
    • Oermann CM R-BG
    • Oermann CM R-BG, McCoy KS, Gibson RL, Quittner AL, Montgomery AB. Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): effect on disease related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA). Pediatr. Pulmonology 44(SUPPL. 32), 296 (2009).
    • (2009) Pediatr. Pulmonology , vol.44 , Issue.SUPPL. 32 , pp. 296
    • McCoy, K.S.1    Gibson, R.L.2    Quittner, A.L.3    Montgomery, A.B.4
  • 39
    • 27144479427 scopus 로고    scopus 로고
    • Development and validation of the Cystic Fibrosis Questionnaire in the United States: A health-related quality-of-life measure for cystic fibrosis
    • Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128(4), 2347-2354 (2005).
    • (2005) Chest , vol.128 , Issue.4 , pp. 2347-2354
    • Quittner, A.L.1    Buu, A.2    Messer, M.A.3    Modi, A.C.4    Watrous, M.5
  • 40
    • 66649116259 scopus 로고    scopus 로고
    • Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection
    • Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 135(6), 1610-1618 (2009).
    • (2009) Chest , vol.135 , Issue.6 , pp. 1610-1618
    • Quittner, A.L.1    Modi, A.C.2    Wainwright, C.3    Otto, K.4    Kirihara, J.5    Montgomery, A.B.6
  • 41
    • 65949085097 scopus 로고    scopus 로고
    • Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data
    • Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, Quittner AL, Montgomery AB. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): interim analysis of 12 month data. J. Cyst. Fibrosis 7(S2), S25 (2008).
    • (2008) J. Cyst. Fibrosis , vol.7
    • Oermann, C.M.1    McCoy, K.S.2    Retsch- Bogart, G.Z.3    Gibson, R.L.4    Quittner, A.L.5    Montgomery, A.B.6
  • 42
    • 77952131777 scopus 로고    scopus 로고
    • Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens
    • Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, McKevitt M. Montgomery AB. Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens. Pediatr. Pulmonol. 44(SUPPL. 32), S335 (2009).
    • (2009) Pediatr. Pulmonol. , vol.44 , Issue.SUPPL. 32
    • Oermann, C.M.1    McCoy, K.S.2    Retsch- Bogart, G.Z.3    Gibson, R.L.4    McKevitt, M.5    Montgomery, A.B.6
  • 43
    • 77952196413 scopus 로고    scopus 로고
    • Antibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis
    • Oermann CM, McCoy KS, Retsch- Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Antibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis. Pediatr. Pulmonology 44(SUPPL. 32), 309 (2009).
    • (2009) Pediatr. Pulmonology , vol.44 , Issue.SUPPL. 32 , pp. 309
    • Oermann, C.M.1    McCoy, K.S.2    Retsch- Bogart, G.Z.3    Gibson, R.L.4    McKevitt, M.5    Montgomery, A.B.6
  • 44
    • 0036736583 scopus 로고    scopus 로고
    • A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
    • Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 20(3), 658-664 (2002).
    • (2002) Eur. Respir. J. , vol.20 , Issue.3 , pp. 658-664
    • Hodson, M.E.1    Gallagher, C.G.2    Govan, J.R.3
  • 45
    • 34248358238 scopus 로고    scopus 로고
    • Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis
    • Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J. Cyst. Fibrosis 5(4), 261-263 (2006).
    • (2006) J. Cyst. Fibrosis , vol.5 , Issue.4 , pp. 261-263
    • Adeboyeku, D.1    Scott, S.2    Hodson, M.E.3
  • 46
    • 77952159044 scopus 로고    scopus 로고
    • Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF)
    • Montgomery AB, Lewis S, Higuchi K, Marshall B, Oermann C. Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF). Am. J. Respir. Crit. Care Med. 179, A1188 (2009).
    • (2009) Am. J. Respir. Crit. Care Med. , vol.179
    • Montgomery, A.B.1    Lewis, S.2    Higuchi, K.3    Marshall, B.4    Oermann, C.5
  • 47
    • 36248953255 scopus 로고    scopus 로고
    • Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health
    • Flume PA, O'Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176(10), 957-969 (2007).
    • (2007) Am. J. Respir. Crit. Care Med. , vol.176 , Issue.10 , pp. 957-969
    • Flume, P.A.1    O'Sullivan, B.P.2    Robinson, K.A.3
  • 48
  • 51
    • 73449119635 scopus 로고    scopus 로고
    • Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): Effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)
    • Oermann CM, McCoy KS, Retsch- Bogart GZ . Gibson RL , Quittner A L , Montgomery AB. Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA). J. Cyst. Fibrosis 8(2 SUPPL.), S28 (2009).
    • (2009) J. Cyst. Fibrosis , vol.8 , Issue.2 SUPPL.
    • Oermann, C.M.1    McCoy, K.S.2    Retsch- Bogart, G.Z.3    Gibson, R.L.4    Quittner, A.L.5    Montgomery, A.B.6
  • 52
    • 34249945743 scopus 로고    scopus 로고
    • A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: A double-blind, placebo- controlled, multicenter study
    • Chuchalin A, Csiszer E, Gyurkovics K et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo- controlled, multicenter study. Paediatr. Drugs 9 (SUPPL. 1), 21-31 (2007).
    • (2007) Paediatr. Drugs , vol.9 , Issue.SUPPL. 1 , pp. 21-31
    • Chuchalin, A.1    Csiszer, E.2    Gyurkovics, K.3
  • 53
    • 70349123019 scopus 로고    scopus 로고
    • Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa
    • Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53(9), 3923-3928 (2009).
    • (2009) Antimicrob. Agents Chemother. , vol.53 , Issue.9 , pp. 3923-3928
    • Sabet, M.1    Miller, C.E.2    Nolan, T.G.3    Senekeo-Effenberger, K.4    Dudley, M.N.5    Griffith, D.C.6
  • 54
    • 54949136128 scopus 로고    scopus 로고
    • Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size
    • Li Z, Zhang Y, Wurtz W et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol. Med. Pulm. Drug Deliv. 21(3), 245-254 (2008).
    • (2008) J. Aerosol. Med. Pulm. Drug Deliv. , vol.21 , Issue.3 , pp. 245-254
    • Li, Z.1    Zhang, Y.2    Wurtz, W.3
  • 55
    • 70349084570 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection
    • Okusanya OO, Bhavnani SM, Hammel J et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother. 53(9), 3847-3854 (2009).
    • (2009) Antimicrob. Agents Chemother. , vol.53 , Issue.9 , pp. 3847-3854
    • Okusanya, O.O.1    Bhavnani, S.M.2    Hammel, J.3
  • 56
    • 34247193128 scopus 로고    scopus 로고
    • Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
    • Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol. 42(4), 307-313 (2007).
    • (2007) Pediatr. Pulmonol. , vol.42 , Issue.4 , pp. 307-313
    • Geller, D.E.1    Konstan, M.W.2    Smith, J.3    Noonberg, S.B.4    Conrad, C.5
  • 57
    • 77955017576 scopus 로고    scopus 로고
    • Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder inhalation in adolescent patients with CF
    • Stass H, Nagelschmitz J, Posselt H. Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder inhalation in adolescent patients with CF. Pediatr. Pulmonol. 44(SUPPL. 32), 302 (2009).
    • (2009) Pediatr. Pulmonol. , vol.44 , Issue.SUPPL. 32 , pp. 302
    • Stass, H.1    Nagelschmitz, J.2    Posselt, H.3
  • 58
    • 34250899751 scopus 로고    scopus 로고
    • Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot study
    • Westerman EM, De Boer AH, Le Brun PP et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J. Cyst. Fibrosis 6(4), 284-292 (2007).
    • (2007) J. Cyst. Fibrosis , vol.6 , Issue.4 , pp. 284-292
    • Westerman, E.M.1    De Boer, A.H.2    Le Brun, P.P.3
  • 59
    • 70349444999 scopus 로고    scopus 로고
    • Antibacterial activities of a fosfomycin/ tobramycin combination: A novel inhaled antibiotic for bronchiectasis
    • MacLeod DL, Barker LM, Sutherland JL et al. Antibacterial activities of a fosfomycin/ tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother. 64(4), 829-836 (2009).
    • (2009) J. Antimicrob. Chemother. , vol.64 , Issue.4 , pp. 829-836
    • MacLeod, D.L.1    Barker, L.M.2    Sutherland, J.L.3
  • 60
    • 77950914953 scopus 로고    scopus 로고
    • Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial
    • Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65(4), 286-291 (2009).
    • (2009) Thorax , vol.65 , Issue.4 , pp. 286-291
    • Ratjen, F.1    Munck, A.2    Kho, P.3    Angyalosi, G.4
  • 61
    • 67349204479 scopus 로고    scopus 로고
    • Early anti- pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study
    • Treggiari MM, Rosenfeld M, Mayer-Hamblett N et al. Early anti- pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp. Clin. Trials 30(3), 256-268 (2009).
    • (2009) Contemp. Clin. Trials , vol.30 , Issue.3 , pp. 256-268
    • Treggiari, M.M.1    Rosenfeld, M.2    Mayer-Hamblett, N.3
  • 62
    • 34147189596 scopus 로고    scopus 로고
    • Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis
    • Lebecque P, Leal T, Zylberberg K, Reychler G, Bossuyt X, Godding V. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibrosis 5(4), 237-244 (2006).
    • (2006) J. Cyst. Fibrosis , vol.5 , Issue.4 , pp. 237-244
    • Lebecque, P.1    Leal, T.2    Zylberberg, K.3    Reychler, G.4    Bossuyt, X.5    Godding, V.6
  • 63
    • 0034546826 scopus 로고    scopus 로고
    • Technical report: Precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs
    • Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 106(6), e89 (2000).
    • (2000) Pediatrics , vol.106 , Issue.6
    • Prober, C.G.1    Walson, P.D.2    Jones, J.3
  • 64
    • 34548048797 scopus 로고    scopus 로고
    • Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    • Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132(2), 562-568 (2007).
    • (2007) Chest , vol.132 , Issue.2 , pp. 562-568
    • Merlo, C.A.1    Boyle, M.P.2    Diener-West, M.3    Marshall, B.C.4    Goss, C.H.5    Lechtzin, N.6
  • 65
    • 70349761385 scopus 로고    scopus 로고
    • Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas: The EPIC study
    • Hamblett NM, Retsch-Bogart GZ, Treggiari M et al. Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas: the EPIC study. Pediatr. Pulmonology 44(SUPPL. 32), 183 (2009).
    • (2009) Pediatr. Pulmonology , vol.44 , Issue.SUPPL. 32 , pp. 183
    • Hamblett, N.M.1    Retsch-Bogart, G.Z.2    Treggiari, M.3
  • 66
    • 0021978780 scopus 로고
    • Aztreonam: The first monobactam
    • Sykes RB, Bonner DP. Aztreonam: the first monobactam. Am. J. Med. 78(2 SUPPL. 1), 2-10 (1985).
    • (1985) Am. J. Med. , vol.78 , Issue.2 SUPPL. 1 , pp. 2-10
    • Sykes, R.B.1    Bonner, D.P.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.